Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pramlintide
Drug ID BADD_D01819
Description Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes.
Indications and Usage For the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.
Marketing Status approved; investigational
ATC Code A10BX05
DrugBank ID DB01278
KEGG ID D05594
MeSH ID C105254
PubChem ID 70691388
TTD Drug ID D0C4AM
NDC Product Code 52416-106
UNII D3FM8FA78T
Synonyms pramlintide | LYS-CYS-ASN-THR-ALA-THR-CYS-ALA-THR-GLN-ARG-LEU-ALA-ASN-PHE-LEU-VAL-HIS-SER-SER-ASN-ASN-PHE-GLY-PRO-ILE-LEU-PRO-PRO-THR-ASN-VAL-GLY-SER-ASN-THR-TYR-NH2 | Symlin | AC 0137 | AC 137 | pramlintide acetate | Tripro-Amylin
Chemical Information
Molecular Formula C171H267N51O53S2
CAS Registry Number 151126-32-8
SMILES CCC(C)C(C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)N2CCCC2C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(= O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC3=CC=C(C=C3 )O)C(=O)N)NC(=O)C4CCCN4C(=O)CNC(=O)C(CC5=CC=CC=C5)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O) N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC6=CNC=N6)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C( CC7=CC=CC=C7)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C (CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C8CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC( C(=O)N8)C(C)O)C)C(C)O)CC(=O)N)NC(=O)C(CCCCN)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Arthralgia15.01.02.001--
Asthenia08.01.01.001--Not Available
Cough22.02.03.001--
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Fatigue08.01.01.002--
Gastrointestinal pain07.01.05.005--
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Hypoglycaemia14.06.03.001; 05.06.03.001--
Injection site reaction12.07.03.015; 08.02.03.014--
Injury12.01.08.004--Not Available
Nausea07.01.07.001--
Pancreatitis07.18.01.001--
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Vomiting07.01.07.003--
Musculoskeletal discomfort15.03.04.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
The 1th Page    1    Total 1 Pages